Skip to main content
SpringerLink
Log in

Potential Novel Therapeutics for Bipolar Disorders

  • Chapter
  • First Online:
Behavioral Neurobiology of Bipolar Disorder and its Treatment

Part of the book series: Current Topics in Behavioral Neurosciences ((CTBN,volume 5))

Abstract

Existing pharmacological treatments for bipolar disorder (BPD), a severe recurrent mood disorder, are in general insufficient for many patients. Despite adequate doses and treatment duration, many individuals with this disease continue to experience mood episode relapses, residual symptoms, and functional impairment. This chapter reviews a number of targets/compounds that could result in putative novel treatments for BPD, including the dynorphin opioid neuropeptide system, the glutamatergic system, the purinergic system, the cholinergic system (muscarinic and nicotinic systems), the oxidative stress system, and the melatonergic system. The arachidonic acid cascade and intracellular signaling cascades (including glycogen synthase kinase 3 and protein kinase C) are also reviewed, as are agents that affect multiple targets (e.g., modafinil, Uridine RG2417). Further study of these and similar agents may improve our understanding of relevant drug targets and their clinical utility as potential therapeutics for this devastating disorder.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Agarwal V, Tripathi A (2009) Memantine in the management of a clinically challenging case of bipolar disorder. Indian J Psychiatry 51:137–138

    PubMed  PubMed Central  Google Scholar 

  • Aguado L, San Antonio A, Perez L, del Valle R, Gomez J (1994) Effects of the NMDA receptor antagonist ketamine on flavor memory: conditioned aversion, latent inhibition, and habituation of neophobia. Behav Neural Biol 61:271–281

    PubMed  CAS  Google Scholar 

  • Akhondzadeh S, Milajerdi MR, Amini H, Tehrani-Doost M (2006) Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial. Bipolar Disord 8:485–489

    PubMed  CAS  Google Scholar 

  • Alaerts M, Venken T, Lenaerts AS, De Zutter S, Norrback KF, Adolfsson R, Del-Favero J (2006) Lack of association of an insertion/deletion polymorphism in the G protein-coupled receptor 50 with bipolar disorder in a Northern Swedish population. Psychiatr Genet 16:235–236

    PubMed  Google Scholar 

  • Andreasen JT, Redrobe JP (2009) Antidepressant-like effects of nicotine and mecamylamine in the mouse forced swim and tail suspension tests: role of strain, test and sex. Behav Pharmacol 20:286–295

    PubMed  CAS  Google Scholar 

  • Andreazza AC, Cassini C, Rosa AR, Leite MC, de Almeida LM, Nardin P, Cunha AB, Cereser KM, Santin A, Gottfried C, Salvador M, Kapczinski F, Goncalves CA (2007) Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatr Res 41:523–529

    PubMed  Google Scholar 

  • Anumonye A, Reading HW, Knight F, Ashcroft GW (1968) Uric-acid metabolism in manic-depressive illness and during lithium therapy. Lancet 1:1290–1293

    PubMed  CAS  Google Scholar 

  • Armstrong SM, McNulty OM, Guardiola-Lemaitre B, Redman JR (1993) Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS). Pharmacol Biochem Behav 46:45–49

    PubMed  CAS  Google Scholar 

  • Banasr M, Soumier A, Hery M, Mocaer E, Daszuta A (2006) Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis. Biol Psychiatry 59:1087–1096

    PubMed  CAS  Google Scholar 

  • Banasr M, Chowdhury GM, Terwilliger R, Newton SS, Duman RS, Behar KL, Sanacora G (2008) Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol Psychiatry (Epub ahead of print)

    Google Scholar 

  • Bannerman DM, Good MA, Butcher SP, Ramsay M, Morris RG (1995) Distinct components of spatial learning revealed by prior training and NMDA receptor blockade. Nature 378:182–186

    PubMed  CAS  Google Scholar 

  • Barber A, Gottschlich R (1997) Novel developments with selective, non-peptidic kappa-opioid receptor agonists. Expert Opin Investig Drugs 6:1351–1368

    PubMed  CAS  Google Scholar 

  • Barden N, Harvey M, Gagne B, Shink E, Tremblay M, Raymond C, Labbe M, Villeneuve A, Rochette D, Bordeleau L, Stadler H, Holsboer F, Muller-Myhsok B (2006) Analysis of single nucleotide polymorphisms in genes in the chromosome 12Q24.31 region points to P2RX7 as a susceptibility gene to bipolar affective disorder. Am J Med Genet B Neuropsychiatr Genet 141B:374–382

    PubMed  CAS  Google Scholar 

  • Basso AM, Bratcher NA, Harris RR, Jarvis MF, Decker MW, Rueter LE (2009) Behavioral profile of P2X7 receptor knockout mice in animal models of depression and anxiety: relevance for neuropsychiatric disorders. Behav Brain Res 198:83–90

    PubMed  CAS  Google Scholar 

  • Bebchuk JM, Arfken CL, Dolan-Manji S, Murphy J, Hasanat K, Manji HK (2000) A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch Gen Psychiatry 57:95–97

    PubMed  CAS  Google Scholar 

  • Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Bush AI (2008) N-acetyl cysteine for depressive symptoms in bipolar disorder – a double-blind randomized placebo-controlled trial. Biol Psychiatry 64:468–475

    PubMed  CAS  Google Scholar 

  • Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351–354

    PubMed  CAS  Google Scholar 

  • Berrocoso E, Rojas-Corrales MO, Mico JA (2004) Non-selective opioid receptor antagonism of the antidepressant-like effect of venlafaxine in the forced swimming test in mice. Neurosci Lett 363:25–28

    PubMed  CAS  Google Scholar 

  • Bersani G, Garavini A (2000) Melatonin add-on in manic patients with treatment resistant insomnia. Prog Neuropsychopharmacol Biol Psychiatry 24:185–191

    PubMed  CAS  Google Scholar 

  • Bertaina-Anglade V, la Rochelle CD, Boyer PA, Mocaer E (2006) Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model. Behav Pharmacol 17:703–713

    PubMed  CAS  Google Scholar 

  • Besson A, Privat AM, Eschalier A, Fialip J (1996) Effects of morphine, naloxone and their interaction in the learned-helplessness paradigm in rats. Psychopharmacology (Berl) 123:71–78

    CAS  Google Scholar 

  • Black MD (2005) Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data. Psychopharmacology (Berl) 179:154–163

    CAS  Google Scholar 

  • Bleakman D, Lodge D (1998) Neuropharmacology of AMPA and kainate receptors. Neuropharmacology 37:1187–1204

    PubMed  CAS  Google Scholar 

  • Burnstock G (2007) Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev 87:659–797

    PubMed  CAS  Google Scholar 

  • Burt T, Sachs GS, Demopulos C (1999) Donepezil in treatment-resistant bipolar disorder. Biol Psychiatry 45:959–964

    PubMed  CAS  Google Scholar 

  • Calabrese JR, Guelfi JD, Perdrizet-Chevallier C (2007) Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disord 9:628–635

    PubMed  CAS  Google Scholar 

  • Cannon DM, Carson RE, Nugent AC, Eckelman WC, Kiesewetter DO, Williams J, Rollis D, Drevets M, Gandhi S, Solorio G, Drevets WC (2006) Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. Arch Gen Psychiatry 63:741–747

    PubMed  CAS  Google Scholar 

  • Carlezon WA Jr, Beguin C, DiNieri JA, Baumann MH, Richards MR, Todtenkopf MS, Rothman RB, Ma Z, Lee DY, Cohen BM (2006) Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther 316:440–447

    PubMed  CAS  Google Scholar 

  • Chartoff EH, Papadopoulou M, MacDonald ML, Parsegian A, Potter D, Konradi C, Carlezon WA Jr (2009) Desipramine reduces stress-activated dynorphin expression and CREB phosphorylation in NAc tissue. Mol Pharmacol 75:704–712

    PubMed  CAS  PubMed Central  Google Scholar 

  • Chen G, Manji HK, Hawver DB, Wright CB, Potter WZ (1994) Chronic sodium valproate selectively decreases protein kinase C alpha and epsilon in vitro. J Neurochem 63:2361–2364

    PubMed  CAS  Google Scholar 

  • Cohen BM, Murphy B (2008) The effects of pentazocine, a kappa agonist, in patients with mania. Int J Neuropsychopharmacol 11:243–247

    PubMed  CAS  Google Scholar 

  • Collingridge GL (1994) Long-term potentiation. A question of reliability. Nature 371:652–653

    PubMed  CAS  Google Scholar 

  • Collingridge GL, Bliss TV (1995) Memories of NMDA receptors and LTP. Trends Neurosci 18:54–56

    PubMed  CAS  Google Scholar 

  • Cryan JF, Kelly PH, Neijt HC, Sansig G, Flor PJ, van Der Putten H (2003) Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic glutamate receptor mGluR7. Eur J Neurosci 17:2409–2417

    PubMed  Google Scholar 

  • Davis KL, Berger PA, Hollister LE, Defraites E (1978) Physostigmine in mania. Arch Gen Psychiatry 35:119–122

    PubMed  CAS  Google Scholar 

  • De Luca V, Likhodi O, Van Tol HH, Kennedy JL, Wong AH (2006) Regulation of alpha7-nicotinic receptor subunit and alpha7-like gene expression in the prefrontal cortex of patients with bipolar disorder and schizophrenia. Acta Psychiatr Scand 114:211–215

    PubMed  Google Scholar 

  • Devoize JL, Rigal F, Eschalier A, Trolese JF, Renoux M (1984) Influence of naloxone on antidepressant drug effects in the forced swimming test in mice. Psychopharmacology (Berl) 84:71–75

    CAS  Google Scholar 

  • Drevets WC, Furey ML (2010) Replication of scopolamine’s antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol Psychiatry (Epub ahead of print)

    Google Scholar 

  • Du J, Gray NA, Falke CA, Chen W, Yuan P, Szabo ST, Einat H, Manji HK (2004) Modulation of synaptic plasticity by antimanic agents: the role of AMPA glutamate receptor subunit 1 synaptic expression. J Neurosci 24(29):6578–6589

    Google Scholar 

  • Du J, Suzuki K, Wei Y, Wang Y, Blumenthal R, Chen Z, Falke C, Zarate CA Jr, Manji HK (2007) The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology 32:793–802

    PubMed  CAS  Google Scholar 

  • Eden Evins A, Demopulos C, Nierenberg A, Culhane MA, Eisner L, Sachs GS (2006) A double-blind, placebo-controlled trial of adjunctive donepezil in treatment-resistant mania. Bipolar Disord 8:75–80

    PubMed  CAS  Google Scholar 

  • Einat H, Yuan P, Szabo ST, Dogra S, Manji HK (2007) Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats: implications for the development of novel therapeutics for bipolar disorder. Neuropsychobiology 55:123–131

    PubMed  CAS  Google Scholar 

  • Eppel AB (2008) Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disord 10:749–750

    PubMed  Google Scholar 

  • Epping-Jordan MP, Watkins SS, Koob GF, Markou A (1998) Dramatic decreases in brain reward function during nicotine withdrawal. Nature 393:76–79

    PubMed  CAS  Google Scholar 

  • Fanelli J, Montgomery C (1996) Use of the analgesic tramadol in antidepressant potentiation. Psychopharmacol Bull 32:442

    Google Scholar 

  • Ferguson SM, Brodkin JD, Lloyd GK, Menzaghi F (2000) Antidepressant-like effects of the subtype-selective nicotinic acetylcholine receptor agonist, SIB-1508Y, in the learned helplessness rat model of depression. Psychopharmacology (Berl) 152:295–303

    CAS  Google Scholar 

  • Fichna J, Janecka A, Piestrzeniewicz M, Costentin J, do Rego J-C (2007) Antidepressant-like effect of endomorphin-1 and endomorphin-2 in mice. Neuropsychopharmacology 32:813–821

    PubMed  CAS  Google Scholar 

  • Friedman E, Hoau Yan W, Levinson D, Connell TA, Singh H (1993) Altered platelet protein kinase C activity in bipolar affective disorder, manic episode. Biol Psychiatry 33:520–525

    PubMed  CAS  Google Scholar 

  • Frizzo ME, Dall’Onder LP, Dalcin KB, Souza DO (2004) Riluzole enhances glutamate uptake in rat astrocyte cultures. Cell Mol Neurobiol 24:123–128

    PubMed  CAS  Google Scholar 

  • Frye MA, Grunze H, Suppes T, McElroy SL, Keck PE Jr, Walden J, Leverich GS, Altshuler LL, Nakelsky S, Hwang S, Mintz J, Post RM (2007) A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry 164:1242–1249

    PubMed  Google Scholar 

  • Garcia LS, Comim CM, Valvassori SS, Reus GZ, Barbosa LM, Andreazza AC, Stertz L, Fries GR, Gavioli EC, Kapczinski F, Quevedo J (2008) Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 32:140–144

    PubMed  CAS  Google Scholar 

  • Gasparini F, Bruno V, Battaglia G, Lukic S, Leonhardt T, Inderbitzin W, Laurie D, Sommer B, Varney MA, Hess SD, Johnson EC, Kuhn R, Urwyler S, Sauer D, Portet C, Schmutz M, Nicoletti F, Flor PJ (1999) (R, S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo. J Pharmacol Exp Ther 289:1678–1687

    PubMed  CAS  Google Scholar 

  • George TP, Sacco KA, Vessicchio JC, Weinberger AH, Shytle RD (2008) Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study. J Clin Psychopharmacol 28:340–344

    PubMed  Google Scholar 

  • Gibbons AS, Scarr E, McLean C, Sundram S, Dean B (2009) Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects. J Affect Disord 116:184–191

    PubMed  CAS  PubMed Central  Google Scholar 

  • Gildengers AG, Butters MA, Chisholm D, Reynolds CF, Mulsant BH (2008) A 12-week open-label pilot study of donepezil for cognitive functioning and instrumental activities of daily living in late-life bipolar disorder. Int J Geriatr Psychiatry 23:693–698

    PubMed  PubMed Central  Google Scholar 

  • Gitlin M (2006) Treatment-resistant bipolar disorder. Mol Psychiatry 11:227–240

    PubMed  CAS  Google Scholar 

  • Goldstein JA (1986) Danazol and the rapid-cycling patient. J Clin Psychiatry 47:153–154

    PubMed  CAS  Google Scholar 

  • Gould TD, Manji HK (2005) Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 30:1223–1237

    PubMed  CAS  Google Scholar 

  • Gould TD, Einat H, Bhat R, Manji HK (2004) AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol 7:387–390

    PubMed  CAS  Google Scholar 

  • Gould TD, Picchini AM, Einat H, Manji HK (2006) Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. Curr Drug Targets 7:1399–1409

    PubMed  CAS  Google Scholar 

  • Gray AM, Spencer PS, Sewell RD (1998) The involvement of the opioidergic system in the antinociceptive mechanism of action of antidepressant compounds. Br J Pharmacol 124:669–674

    PubMed  CAS  PubMed Central  Google Scholar 

  • Hahn CG, Friedman E (1999) Abnormalities in protein kinase C signaling and the pathophysiology of bipolar disorder. Bipolar Disord 1:81–86

    PubMed  CAS  Google Scholar 

  • Hallam KT, Olver JS, Norman TR (2005) Melatonin sensitivity to light in monozygotic twins discordant for bipolar I disorder. Aust N Z J Psychiatry 39:947

    PubMed  Google Scholar 

  • Hurd YL (2002) Subjects with major depression or bipolar disorder show reduction of prodynorphin mRNA expression in discrete nuclei of the amygdaloid complex. Mol Psychiatry 7:75–81

    PubMed  CAS  Google Scholar 

  • Janowsky DS, el-Yousef MK, Davis JM, Sekerke HJ (1972) A cholinergic–adrenergic hypothesis of mania and depression. Lancet 2:632–635

    PubMed  CAS  Google Scholar 

  • Jellinek T (1977) Mood elevating effect of trihexyphenidyl and biperiden in individuals taking antipsychotic medication. Dis Nerv Syst 38:353–355

    PubMed  CAS  Google Scholar 

  • Jensen JE, Daniels M, Haws C, Bolo NR, Lyoo IK, Yoon SJ, Cohen BM, Stoll AL, Rusche JR, Renshaw PF (2008) Triacetyluridine (TAU) decreases depressive symptoms and increases brain pH in bipolar patients. Exp Clin Psychopharmacol 16:199–206

    PubMed  CAS  Google Scholar 

  • Jope RS (2003) Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci 24:441–443

    PubMed  CAS  Google Scholar 

  • Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, Leon AC, Rice JA, Keller MB (2002) The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 59:530–537

    PubMed  Google Scholar 

  • Jutkiewicz EM (2006) The antidepressant-like effects of delta-opioid receptor agonists. Mol Interv 6:162–169

    PubMed  CAS  Google Scholar 

  • Kasper S, Moises HW, Beckmann H (1981) The anticholinergic biperiden in depressive disorders. Pharmacopsychiatria 14:195–198

    PubMed  CAS  Google Scholar 

  • Kaster MP, Rosa AO, Rosso MM, Goulart EC, Santos AR, Rodrigues AL (2004) Adenosine administration produces an antidepressant-like effect in mice: evidence for the involvement of A1 and A2A receptors. Neurosci Lett 355:21–24

    PubMed  CAS  Google Scholar 

  • Kennedy SH, Emsley R (2006) Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 16:93–100

    PubMed  CAS  Google Scholar 

  • Khairova RA, Machado-Vieira R, Du J, Manji HK (2009) A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int J Neuropsychopharmacol 12:561–578

    PubMed  CAS  PubMed Central  Google Scholar 

  • Khouzam HR, Kissmeyer PM (1996) Physostigmine temporarily and dramatically reversing acute mania. Gen Hosp Psychiatry 18:203–204

    PubMed  CAS  Google Scholar 

  • Kinney GG, O’Brien JA, Lemaire W, Burno M, Bickel DJ, Clements MK, Chen TB, Wisnoski DD, Lindsley CW, Tiller PR, Smith S, Jacobson MA, Sur C, Duggan ME, Pettibone DJ, Conn PJ, Williams DL Jr (2005) A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J Pharmacol Exp Ther 313:199–206

    PubMed  CAS  Google Scholar 

  • Kittner H, Krugel U, Illes P (2001) The purinergic P2 receptor antagonist pyridoxalphosphate-6-azophenyl-2?4?-disulphonic acid prevents both the acute locomotor effects of amphetamine and the behavioural sensitization caused by repeated amphetamine injections in rats. Neuroscience 102:241–243

    PubMed  CAS  Google Scholar 

  • Knapp RJ, Goldenberg R, Shuck C, Cecil A, Watkins J, Miller C, Crites G, Malatynska E (2002) Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model. Eur J Pharmacol 440:27–35

    PubMed  CAS  Google Scholar 

  • Krystal JH (2008) Capitalizing on extrasynaptic glutamate neurotransmission to treat antipsychotic-resistant symptoms in schizophrenia. Biol Psychiatry 64:358–360

    PubMed  Google Scholar 

  • Kulkarni J, Garland KA, ScAffi A, Headey B, Anderson R, de Castella A, Fitzgerald P, Davis SR (2006) A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder. Psychoneuroendocrinology 31:543–547

    PubMed  CAS  Google Scholar 

  • Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N (2002) Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct 20:171–175

    PubMed  CAS  Google Scholar 

  • Lara DR, Dall’Igna OP, Ghisolfi ES, Brunstein MG (2006) Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications. Prog Neuropsychopharmacol Biol Psychiatry 30:617–629

    PubMed  CAS  Google Scholar 

  • Lee HJ, Rao JS, Chang L, Rapoport SI, Kim HW (2008) Chronic imipramine but not bupropion increases arachidonic acid signaling in rat brain: is this related to ‘switching’ in bipolar disorder? Mol Psychiatry (Epub ahead of print)

    Google Scholar 

  • Lewy AJ, Wehr TA, Goodwin FK, Newsome DA, Rosenthal NE (1981) Manic-depressive patients may be supersensitive to light. Lancet 1:383–384

    PubMed  CAS  Google Scholar 

  • Lewy AJ, Nurnberger JI Jr, Wehr TA, Pack D, Becker LE, Powell RL, Newsome DA (1985) Supersensitivity to light: possible trait marker for manic-depressive illness. Am J Psychiatry 142:725–727

    PubMed  CAS  Google Scholar 

  • Littner M, Johnson SF, McCall WV, Anderson WM, Davila D, Hartse SK, Kushida CA, Wise MS, Hirschkowitz M, Woodson BT, Standards of Practice Comittee (2001) Practice parameters for the treatment of narcolepsy: an update for 2000. Sleep 24:451–466

    PubMed  CAS  Google Scholar 

  • Loo H, Hale A, D’Haenen H (2002) Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 17:239–247

    PubMed  CAS  Google Scholar 

  • Lourenco Da Silva A, Hoffmann A, Dietrich MO, Dall’Igna OP, Souza DO, Lara DR (2003) Effect of riluzole on MK-801 and amphetamine-induced hyperlocomotion. Neuropsychobiology 48:27–30

    PubMed  CAS  Google Scholar 

  • Lucae S, Salyakina D, Barden N, Harvey M, Gagne B, Labbe M, Binder EB, Uhr M, Paez-Pereda M, Sillaber I, Ising M, Bruckl T, Lieb R, Holsboer F, Muller-Myhsok B (2006) P2RX7, a gene coding for a purinergic ligand-gated ion channel, is associated with major depressive disorder. Hum Mol Genet 15:2438–2445

    PubMed  CAS  Google Scholar 

  • Luo X, Kranzler HR, Zuo L, Wang S, Blumberg HP, Gelernter J (2005) CHRM2 gene predisposes to alcohol dependence, drug dependence and affective disorders: results from an extended case-control structured association study. Hum Mol Genet 14:2421–2434

    PubMed  CAS  Google Scholar 

  • Machado-Vieira R, Lara DR, Souza DO, Kapczinski F (2001) Therapeutic efficacy of allopurinol in mania associated with hyperuricemia. J Clin Psychopharmacol 21:621–622

    PubMed  CAS  Google Scholar 

  • Machado-Vieira R, Lara DR, Souza DO, Kapczinski F (2002) Purinergic dysfunction in mania: an integrative model. Med Hypotheses 58:297–304

    PubMed  CAS  Google Scholar 

  • Machado-Vieira R, Andreazza AC, Viale CI, Zanatto V, Cereser V Jr, da Silva VR, Kapczinski F, Portela LV, Souza DO, Salvador M, Gentil V (2007) Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett 421:33–36

    PubMed  CAS  Google Scholar 

  • Machado-Vieira R, Soares JC, Lara DR, Luckenbaugh DA, Busnello JV, Marca G, Cunha A, Souza DO, Zarate CA Jr, Kapczinski F (2008) A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. J Clin Psychiatry 69:1237–1245

    PubMed  CAS  PubMed Central  Google Scholar 

  • Machado-Vieira R, Manji HK, Zarate CA (2009) The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist 15:525–539

    PubMed  CAS  PubMed Central  Google Scholar 

  • Maeng S, Zarate CA Jr, Du J, Schloesser RJ, McCammon J, Chen G, Manji HK (2008) Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 63:349–352

    PubMed  CAS  Google Scholar 

  • Mague SD, Pliakas AM, Todtenkopf MS, Tomasiewicz HC, Zhang Y, Stevens WC Jr, Jones RM, Portoghese PS, Carlezon WA Jr (2003) Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther 305:323–330

    PubMed  CAS  Google Scholar 

  • Manji HK, Lenox RH (1999) Ziskind–Somerfeld Research Award. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol Psychiatry 46:1328–1351

    PubMed  CAS  Google Scholar 

  • Manji HK, Etcheberrigaray R, Chen G, Olds JL (1993) Lithium decreases membrane-associated protein kinase C in hippocampus: selectivity for the alpha isozyme. J Neurochem 61:2303–2310

    PubMed  CAS  Google Scholar 

  • Marinho MM, de Sousa FC, de Bruin VM, Vale MR, Viana GS (1998) Effects of lithium, alone or associated with pilocarpine, on muscarinic and dopaminergic receptors and on phosphoinositide metabolism in rat hippocampus and striatum. Neurochem Int 33:299–306

    PubMed  CAS  Google Scholar 

  • Meador-Woodruff JH, Hogg AJ Jr, Smith RE (2001) Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder. Brain Res Bull 55(5):631–640

    Google Scholar 

  • Meloni D, Gambarana C, De Montis MG, Dal Pra P, Taddei I, Tagliamonte A (1993) Dizocilpine antagonizes the effect of chronic imipramine on learned helplessness in rats. Pharmacol Biochem Behav 46:423–426

    PubMed  CAS  Google Scholar 

  • Mickley GA, Schaldach MA, Snyder KJ, Balogh SA, Len T, Neimanis K, Goulis P, Hug J, Sauchak K, Remmers-Roeber DR, Walker C, Yamamoto BK (1998) Ketamine blocks a conditioned taste aversion (CTA) in neonatal rats. Physiol Behav 64:381–390

    PubMed  CAS  Google Scholar 

  • Millan MJ, Brocco M, Gobert A, Dekeyne A (2005) Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berl) 177:448–458

    CAS  Google Scholar 

  • Miller DK, Segert IL (2005) Mecamylamine attenuates ephedrine-induced hyperactivity in rats. Pharmacol Biochem Behav 81:165–169

    PubMed  CAS  Google Scholar 

  • Mineur YS, Somenzi O, Picciotto MR (2007) Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6 J mice. Neuropharmacology 52:1256–1262

    PubMed  CAS  PubMed Central  Google Scholar 

  • Miu P, Jarvie KR, Radhakrishnan V, Gates MR, Ogden A, Ornstein PL, Zarrinmayeh H, Ho K, Peters D, Grabell J, Gupta A, Zimmerman DM, Bleakman D (2001) Novel AMPA receptor potentiators LY392098 and LY404187: effects on recombinant human AMPA receptors in vitro. Neuropharmacology 40:976–983

    PubMed  CAS  Google Scholar 

  • Mizuta I, Ohta M, Ohta K, Nishimura M, Mizuta E, Kuno S (2001) Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes. Neurosci Lett 310:117–120

    PubMed  CAS  Google Scholar 

  • Moghaddam B, Adams B, Verma A, Daly D (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17:2921–2927

    PubMed  CAS  Google Scholar 

  • Montgomery SA, Kasper S (2007) Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol 22:283–291

    PubMed  Google Scholar 

  • Muller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Muller B, Spellmann I, Hetzel G, Maino K, Kleindienst N, Moller HJ, Arolt V, Riedel M (2006) The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 11:680–684

    PubMed  CAS  Google Scholar 

  • Nagayama H (1996) Chronic administration of imipramine and lithium changes the phase-angle relationship between the activity and core body temperature circadian rhythms in rats. Chronobiol Int 13:251–259

    PubMed  CAS  Google Scholar 

  • Nery FG, Monkul ES, Hatch JP, Fonseca M, Zunta-Soares GB, Frey BN, Bowden CL, Soares JC (2008) Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol 23:87–94

    PubMed  CAS  Google Scholar 

  • Ng F, Berk M, Dean O, Bush AI (2008) Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 11:851–876

    PubMed  CAS  Google Scholar 

  • Nierenberg A (2009) Low-dose buspirone, melatonin and low-dose bupropion added to mood stabilizers for severe treatment-resistant bipolar depression. Psychother Psychosom 78:391–393

    PubMed  Google Scholar 

  • Nurnberger JI Jr, Adkins S, Lahiri DK, Mayeda A, Hu K, Lewy A, Miller A, Bowman ES, Miller MJ, Rau L, Smiley C, Davis-Singh D (2000) Melatonin suppression by light in euthymic bipolar and unipolar patients. Arch Gen Psychiatry 57:572–579

    PubMed  CAS  Google Scholar 

  • Ogawa N, Ueki H (2003) Secondary mania caused by caffeine. Gen Hosp Psychiatry 25:138–139

    PubMed  Google Scholar 

  • Ongur D, Prescot AP, Jensen JE, Cohen BM, Renshaw PF (2009) Creatine abnormalities in schizophrenia and bipolar disorder. Psychiatry Res 172:44–48

    PubMed  CAS  PubMed Central  Google Scholar 

  • Overstreet DH (1993) The Flinders sensitive line rats: a genetic animal model of depression. Neurosci Biobehav Rev 17:51–68

    PubMed  CAS  Google Scholar 

  • Padovan CM, Guimaraes FS (2004) Antidepressant-like effects of NMDA-receptor antagonist injected into the dorsal hippocampus of rats. Pharmacol Biochem Behav 77:15–19

    PubMed  CAS  Google Scholar 

  • Pae CU, Marks DM, Han C, Patkar AA (2008) Does minocycline have antidepressant effect? Biomed Pharmacother 62:308–311

    PubMed  CAS  Google Scholar 

  • Palucha A, Pilc A (2007) Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. Pharmacol Ther 115:116–147

    PubMed  CAS  Google Scholar 

  • Pandey GN, Ren X, Rizavi HS, Dwivedi Y (2009) Glycogen synthase kinase-3beta in the platelets of patients with mood disorders: effect of treatment. J Psychiatr Res (Epub ahead of print)

    Google Scholar 

  • Papp M, Moryl E (1993) New evidence for the antidepressant activity of MK-801, a non-competitive antagonist of NMDA receptors. Pol J Pharmacol 45:549–553

    PubMed  CAS  Google Scholar 

  • Papp M, Gruca P, Boyer PA, Mocaer E (2003) Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology 28:694–703

    PubMed  CAS  Google Scholar 

  • Pitkanen A, Mathiesen C, Ronn LC, Moller A, Nissinen J (2007) Effect of novel AMPA antagonist, NS1209, on status epilepticus. An experimental study in rat. Epilepsy Res 74:45–54

    PubMed  Google Scholar 

  • Plante DT (2008) Treatment-emergent hypomania or mania with modafinil. Am J Psychiatry 165:134–135, author reply 135

    PubMed  Google Scholar 

  • Quiroz JA, Gray NA, Kato T, Manji HK (2008) Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 33:2551–2565

    PubMed  CAS  Google Scholar 

  • Rabenstein RL, Caldarone BJ, Picciotto MR (2006) The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not beta2- or alpha7-nicotinic acetylcholine receptor subunit knockout mice. Psychopharmacology (Berl) 189:395–401

    CAS  Google Scholar 

  • Ragnauth A, Schuller A, Morgan M, Chan J, Ogawa S, Pintar J, Bodnar RJ, Pfaff DW (2001) Female preproenkephalin-knockout mice display altered emotional responses. Proc Natl Acad Sci USA 98:1958–1963

    PubMed  CAS  PubMed Central  Google Scholar 

  • Ranjan S, Chandra PS (2005) Modafinil-induced irritability and aggression? A report of 2 bipolar patients. J Clin Psychopharmacol 25:628–629

    PubMed  Google Scholar 

  • Rao JS, Bazinet RP, Rapoport SI, Lee HJ (2007) Chronic treatment of rats with sodium valproate downregulates frontal cortex NF-kappaB DNA binding activity and COX-2 mRNA. Bipolar Disord 9:513–520

    PubMed  CAS  Google Scholar 

  • Rao V, Ovitt L, Robbins B (2008) Donepezil induced hypomania. J Neuropsychiatry Clin Neurosci 20:107

    PubMed  Google Scholar 

  • Rapoport SI, Basselin M, Kim HW, Rao JS (2009) Bipolar disorder and mechanisms of action of mood stabilizers. Brain Res Rev 61:185–209

    PubMed  CAS  PubMed Central  Google Scholar 

  • Rayasam GV, Tulasi VK, Sodhi R, Davis JA, Ray A (2009) Glycogen synthase kinase 3: more than a namesake. Br J Pharmacol 156:885–898

    PubMed  CAS  PubMed Central  Google Scholar 

  • Redman JR, Francis AJ (1998) Entrainment of rat circadian rhythms by the melatonin agonist S-20098 requires intact suprachiasmatic nuclei but not the pineal. J Biol Rhythms 13:39–51

    PubMed  CAS  Google Scholar 

  • Reindl JD, Rowan K, Carey AN, Peng X, Neumeyer JL, McLaughlin JP (2008) Antidepressant-like effects of the novel kappa opioid antagonist MCL-144B in the forced-swim test. Pharmacology 81:229–235

    PubMed  CAS  Google Scholar 

  • Rimoy GH, Wright DM, Bhaskar NK, Rubin PC (1994) The cardiovascular and central nervous system effects in the human of U-62066E. A selective opioid receptor agonist. Eur J Clin Pharmacol 46:203–207

    PubMed  CAS  Google Scholar 

  • Rogawski MA (2006) Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 69:273–294

    PubMed  CAS  PubMed Central  Google Scholar 

  • Roitman S, Green T, Osher Y, Karni N, Levine J (2007) Creatine monohydrate in resistant depression: a preliminary study. Bipolar Disord 9:754–758

    PubMed  CAS  Google Scholar 

  • Rojas-Corrales MO, Gibert-Rahola J, Mico JA (1998) Tramadol induces antidepressant-type effects in mice. Life Sci 63:PL175–PL180

    PubMed  CAS  Google Scholar 

  • Rojas-Corrales MO, Berrocoso E, Gibert-Rahola J, Mico JA (2002) Antidepressant-like effects of tramadol and other central analgesics with activity on monoamines reuptake, in helpless rats. Life Sci 72:143–152

    PubMed  CAS  Google Scholar 

  • Rojas-Corrales MO, Berrocoso E, Gibert-Rahola J, Mico JA (2004) Antidepressant-like effect of tramadol and its enantiomers in reserpinized mice: comparative study with desipramine, fluvoxamine, venlafaxine and opiates. J Psychopharmacol 18:404–411

    PubMed  CAS  Google Scholar 

  • Ross BM, Brooks RJ, Lee M, Kalasinsky KS, Vorce SP, Seeman M, Fletcher PJ, Turenne SD (2002) Cyclooxygenase inhibitor modulation of dopamine-related behaviours. Eur J Pharmacol 450:141–151

    PubMed  CAS  Google Scholar 

  • Rowntree DW, Nevin S, Wilson A (1950) The effects of diisopropylfluorophosphonate in schizophrenia and manic depressive psychosis. J Neurol Neurosurg Psychiatry 13:47–62

    PubMed  CAS  PubMed Central  Google Scholar 

  • Salvadore G, Viale CI, Luckenbaugh DA, Zanatto VC, Portela LW, Souza DO, Zarate CA Jr, Machado-Vieira R (2010) Increased uric acid levels in drug-naive subjects with bipolar disorder during first manic episode. Prog Neuropsychopharmacol Biol Psychiatry (Epub ahead of print)

    Google Scholar 

  • Sanacora G, Zarate CA, Krystal JH, Manji HK (2008) Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 7:426–437

    PubMed  CAS  PubMed Central  Google Scholar 

  • Schoenknecht P, Olbrich S, Sander C, Spindler P, Hegerl U (2010) Treatment of acute mania with modafinil monotherapy. Biol Psychiatry (Epub ahead of print)

    Google Scholar 

  • Schwarzer C (2009) 30 Years of dynorphins – new insights on their functions in neuropsychiatric diseases. Pharmacol Ther 123:353–370

    PubMed  CAS  PubMed Central  Google Scholar 

  • Segal M, Avital A, Drobot M, Lukanin A, Derevenski A, Sandbank S, Weizman A (2007) Serum creatine kinase level in unmedicated nonpsychotic, psychotic, bipolar and schizoaffective depressed patients. Eur Neuropsychopharmacol 17:194–198

    PubMed  CAS  Google Scholar 

  • Semba J, Mataki C, Yamada S, Nankai M, Toru M (1998) Antidepressant-like effects of chronic nicotine on learned helplessness paradigm in rats. Biol Psychiatry 43:389–391

    PubMed  CAS  Google Scholar 

  • Shapira NA, Verduin ML, DeGraw JD (2001) Treatment of refractory major depression with tramadol monotherapy. J Clin Psychiatry 62:205–206

    PubMed  CAS  Google Scholar 

  • Shirayama Y, Ishida H, Iwata M, Hazama GI, Kawahara R, Duman RS (2004) Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects. J Neurochem 90:1258–1268

    PubMed  CAS  Google Scholar 

  • Shytle RD, Silver AA, Sanberg PR (2000) Comorbid bipolar disorder in Tourette’s syndrome responds to the nicotinic receptor antagonist mecamylamine (Inversine). Biol Psychiatry 48:1028–1031

    PubMed  CAS  Google Scholar 

  • Shytle RD, Silver AA, Sheehan KH, Sheehan DV, Sanberg PR (2002) Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence with mecamylamine. Depress Anxiety 16:89–92

    PubMed  Google Scholar 

  • Silvestre JS, Nadal R, Pallares M, Ferre N (1997) Acute effects of ketamine in the holeboard, the elevated-plus maze, and the social interaction test in Wistar rats. Depress Anxiety 5:29–33

    PubMed  CAS  Google Scholar 

  • Skolnick P, Miller R, Young A, Boje K, Trullas R (1992) Chronic treatment with 1-aminocyclopropanecarboxylic acid desensitizes behavioral responses to compounds acting at the N-methyl-d-aspartate receptor complex. Psychopharmacology (Berl) 107:489–496

    CAS  Google Scholar 

  • Sokolski KN, Nguyen BD, DeMet EM (2000) Decreases in dilated pupil size in depressed patients with age may reflect adrenergic changes. Psychiatry Res 94:267–272

    PubMed  CAS  Google Scholar 

  • Spencer C (2000) The efficacy of intramuscular tramadol as a rapid-onset antidepressant. Aust N Z J Psychiatry 34:1032–1033

    PubMed  CAS  Google Scholar 

  • Streck EL, Amboni G, Scaini G, Di-Pietro PB, Rezin GT, Valvassori SS, Luz G, Kapczinski F, Quevedo J (2008) Brain creatine kinase activity in an animal model of mania. Life Sci 82:424–429

    PubMed  CAS  Google Scholar 

  • Tejedor-Real P, Mico JA, Maldonado R, Roques BP, Gibert-Rahola J (1995) Implication of endogenous opioid system in the learned helplessness model of depression. Pharmacol Biochem Behav 52:145–152

    PubMed  CAS  Google Scholar 

  • Teng CT, Demetrio FN (2006) Memantine may acutely improve cognition and have a mood stabilizing effect in treatment resistant bipolar disorder. Rev Bras Psiquiatr 28:252–254

    PubMed  Google Scholar 

  • Thomson PA, Wray NR, Thomson AM, Dunbar DR, Grassie MA, Condie A, Walker MT, Smith DJ, Pulford DJ, Muir W, Blackwood DH, Porteous DJ (2005) Sex-specific association between bipolar affective disorder in women and GPR50, an X-linked orphan G protein-coupled receptor. Mol Psychiatry 10:470–478

    PubMed  CAS  Google Scholar 

  • Tizabi Y, Overstreet DH, Rezvani AH, Louis VA, Clark E Jr, Janowsky DS, Kling MA (1999) Antidepressant effects of nicotine in an animal model of depression. Psychopharmacology (Berl) 142:193–199

    CAS  Google Scholar 

  • Trullas R, Skolnick P (1990) Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 185:1–10

    PubMed  CAS  Google Scholar 

  • Van Oekelen D, Luyten WH, Leysen JE (2003) 5-HT2A and 5-HT2C receptors and their atypical regulation properties. Life Sci 72:2429–2449

    PubMed  Google Scholar 

  • Velentgas P, West W, Cannuscio CC, Watson DJ, Walker AM (2006) Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications. Pharmacoepidemiol Drug Saf 15:641–652

    PubMed  CAS  Google Scholar 

  • Walsh SL, Strain EC, Abreu ME, Bigelow GE (2001) Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl) 157:151–162

    CAS  Google Scholar 

  • Watkins J, Collingridge G (1994) Phenylglycine derivatives as antagonists of metabotropic glutamate receptors. Trends Pharmacol Sci 15:333–342

    PubMed  CAS  Google Scholar 

  • Wittmann W, Schunk E, Rosskothen I, Gaburro S, Singewald N, Herzog H, Schwarzer C (2009) Prodynorphin-derived peptides are critical modulators of anxiety and regulate neurochemistry and corticosterone. Neuropsychopharmacology 34:775–785

    PubMed  CAS  PubMed Central  Google Scholar 

  • Wolf J, Fiedler U, Anghelescu I, Schwertfeger N (2006) Manic switch in a patient with treatment-resistant bipolar depression treated with modafinil. J Clin Psychiatry 67:1817

    PubMed  Google Scholar 

  • Yalcin I, Aksu F, Bodard S, Chalon S, Belzung C (2007) Antidepressant-like effect of tramadol in the unpredictable chronic mild stress procedure: possible involvement of the noradrenergic system. Behav Pharmacol 18:623–631

    PubMed  CAS  Google Scholar 

  • Yoon SJ, Lyoo IK, Haws C, Kim TS, Cohen BM, Renshaw PF (2009) Decreased glutamate/glutamine levels may mediate cytidine’s efficacy in treating bipolar depression: a longitudinal proton magnetic resonance spectroscopy study. Neuropsychopharmacology 34:1810–1818

    PubMed  CAS  Google Scholar 

  • Young LT, Wang JF, Woods CM, Robb JC (1999) Platelet protein kinase C alpha levels in drug-free and lithium-treated subjects with bipolar disorder. Neuropsychobiology 40:63–66

    PubMed  CAS  Google Scholar 

  • Zarate CA, Manji HK (2009) Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder. CNS Drugs 23:569–582

    PubMed  CAS  PubMed Central  Google Scholar 

  • Zarate CA, Quiroz J, Payne J, Manji HK (2002) Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders. Psychopharmacol Bull 36:35–83

    PubMed  Google Scholar 

  • Zarate CA Jr, Du J, Quiroz J, Gray NA, Denicoff KD, Singh J, Charney DS, Manji HK (2003) Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. Ann N Y Acad Sci 1003:273–291

    PubMed  CAS  Google Scholar 

  • Zarate CA Jr, Payne JL, Quiroz J, Sporn J, Denicoff KK, Luckenbaugh D, Charney DS, Manji HK (2004) An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 161:171–174

    PubMed  Google Scholar 

  • Zarate CA Jr, Quiroz JA, Singh JB, Denicoff KD, De Jesus G, Luckenbaugh DA, Charney DS, Manji HK (2005) An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 57:430–432

    PubMed  CAS  Google Scholar 

  • Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856–864

    PubMed  CAS  Google Scholar 

  • Zarate CA Jr, Singh JB, Carlson PJ, Quiroz J, Jolkovsky L, Luckenbaugh DA, Manji HK (2007) Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord 9:561–570

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We would like to acknowledge the support of the Intramural Research Program of the National Institute of Mental Heath, the Stanley Medical Research Institute, and NARSAD. Ioline Henter provided invaluable editorial assistance. Drs Zarate and Manji are listed among the inventors on a patent application submitted for the use of ketamine in depression. They have assigned their rights on the patent to the US government.

Author information

Authors and Affiliations

  1. Experimental Therapeutics, Mood and Anxiety Disorders Research Program, National Institute of Mental Health, National Institutes of Health, 10 Center Drive, Mark O. Hatfield CRC, Unit 7 SE, Rm. 7-3445, Bethesda, MD, 20892, USA

    Rodrigo Machado-Vieira

  2. LIM-Institute of Psychiatry, University of Sao Paulo, Sao Paulo, Brazil

    Rodrigo Machado-Vieira

  3. Johnson and Johnson Pharmaceutical Research and Development, 1125 Trenton-Harbourton Road, E32000, Titusville, NJ, USA

    Husseini K. Manji

  4. Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Mark O. Hatfield Clinical Research Center, 10 Center Dr., Unit 7 SE, Rm 7-3465, Bethesda, MD, 20892, USA

    Carlos A. Zarate Jr.

Authors
  1. Rodrigo Machado-Vieira
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Husseini K. Manji
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carlos A. Zarate Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carlos A. Zarate Jr. .

Editor information

Editors and Affiliations

  1. Research & Development, LLC, Johnson & Johnson Pharmaceutical, Trenton-Habourton Road 1125, Titusville, 08560, New Jersey, USA

    Husseini K. Manji

  2. Mark O. Hatfield Clinical Res. Center, Lab. of Molecular Pathophysiology, National Institute of Mental Health, Center Drive 10, Bethesda, 20892, Maryland, USA

    Carlos A. Zarate Jr.

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Machado-Vieira, R., Manji, H.K., Zarate, C.A. (2010). Potential Novel Therapeutics for Bipolar Disorders. In: Manji, H., Zarate Jr., C. (eds) Behavioral Neurobiology of Bipolar Disorder and its Treatment. Current Topics in Behavioral Neurosciences, vol 5. Springer, Berlin, Heidelberg. https://doi.org/10.1007/7854_2010_51

Download citation

Publish with us

Policies and ethics

Search

Navigation